Bank Julius Baer & Co. Ltd, Zurich Intellia Therapeutics, Inc. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

$26 Billion
Q1 2024

A detailed history of Bank Julius Baer & Co. Ltd, Zurich transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Bank Julius Baer & Co. Ltd, Zurich holds 1,897 shares of NTLA stock, worth $42,018. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,897

Previous 1,907 0.52%

Holding current value

$42,018

Previous $58,000 10.34%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$23.82 - $32.8 $238 - $328	-10 Reduced 0.52%	1,897 $52,000
Q4 2023 May 16, 2024	BUY	$23.16 - $32.34 $231 - $323	10 Added 0.53%	1,907 $58,000
Q4 2023 Feb 02, 2024	SELL	$23.16 - $32.34 $16,003 - $22,346	-691 Reduced 26.6%	1,907 $58,000
Q3 2023 Nov 13, 2023	SELL	$31.62 - $45.78 $224,565 - $325,129	-7,102 Reduced 73.22%	2,598 $82,000
Q2 2023 Jul 24, 2023	BUY	$34.58 - $46.03 $335,426 - $446,491	9,700 New	9,700 $396,000

Q1 2023 May 11, 2023	BUY	$33.3 - $44.82 $53,279 - $71,712	1,600 Added 16.93%	11,051 $412,000
Q4 2022 Jan 24, 2023	SELL	$33.21 - $62.69 $49,648 - $93,721	-1,495 Reduced 13.66%	9,451 $330,000
Q3 2022 Nov 04, 2022	BUY	$53.92 - $71.7 $81,041 - $107,765	1,503 Added 15.92%	10,946 $613,000
Q2 2022 Jul 22, 2022	SELL	$38.49 - $76.21 $95,493 - $189,077	-2,481 Reduced 20.81%	9,443 $489,000
Q1 2022 May 09, 2022	SELL	$58.27 - $118.99 $93,232 - $190,384	-1,600 Reduced 11.83%	11,924 $867,000
Q4 2021 Feb 15, 2022	BUY	$100.76 - $138.36 $1.36 Million - $1.87 Million	13,524 New	13,524 $1.6 Million
Q1 2021 May 10, 2021	SELL	$46.59 - $83.68 $305,770 - $549,191	-6,563 Closed	0 $0
Q4 2020 Feb 24, 2021	BUY	$18.83 - $63.53 $3,973 - $13,404	211 Added 3.32%	6,563 $357,000
Q4 2020 Feb 12, 2021	BUY	$18.83 - $63.53 $119,608 - $403,542	6,352 New	6,352 $357,000

Others Institutions Holding NTLA

# of Institutions

313

Shares Held

89.3M

Call Options Held

686K

Put Options Held

599K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $1.68B
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

News

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.

Account

Bank Julius Baer & Co. Ltd, Zurich Intellia Therapeutics, Inc. Transaction History